Identification of abrogated pathways in fallopian tube epithelium from BRCA1 mutation carriers

Journal of Pathology

Volumn 225, Issue 1, 2011, Pages 106-117

  George, Sophia H L ^a,b   Greenaway, James ^a,c   Milea, Anca ^b,c   Clary, Victoria ^a   Shaw, Sanjeev ^a   Sharma, Monika ^a   Virtanen, Carl ^a   Shaw, Patricia A ^a,c  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

BRCA1; C EBP ; fallopian tube; GADD45 ; NAMPT; serous carcinoma; STAT3

Indexed keywords

BRCA1 PROTEIN; CCAAT ENHANCER BINDING PROTEIN DELTA; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 3;

ANALYSIS OF VARIANCE; ARTICLE; CANCER RISK; CARCINOGENESIS; DISEASE CARRIER; FOLLICULAR PHASE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE MUTATION; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; LUTEAL PHASE; NUCLEOTIDE SEQUENCE; OVARY CANCER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; TUMOR MICROENVIRONMENT; UTERINE TUBE MUCOSA;

ADULT; CASE-CONTROL STUDIES; CLUSTER ANALYSIS; CYSTADENOCARCINOMA, SEROUS; EPITHELIUM; FALLOPIAN TUBE NEOPLASMS; FALLOPIAN TUBES; FEMALE; FOLLICULAR PHASE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENES, BRCA1; HETEROZYGOTE; HUMANS; LUTEAL PHASE; MICRODISSECTION; MIDDLE AGED; MUTATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PRECANCEROUS CONDITIONS; SIGNAL TRANSDUCTION;

EID: 79960903100     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2927     Document Type: Article

References (45)

1. Shaw PA, McLaughlin JR, Zweemer RP, et al., Histopathologic features of genetically determined ovarian cancer. Int J Gynecol Pathol 2002; 21: 407-411.
2. Risch HA, McLaughlin JR, Cole DE, et al., Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 2001; 68: 700-710. (Pubitemid 32203724)
3. Lee Y, Medeiros F, Kindelberger D, et al., Advances in the recognition of tubal intraepithelial carcinoma: applications to cancer screening and the pathogenesis of ovarian cancer. Adv Anat Pathol 2006; 13: 1-7. (Pubitemid 44357143)
4. Medeiros F, Muto MG, Lee Y, et al., The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol 2006; 30: 230-236. (Pubitemid 43740193)
5. Shaw PA, Rouzbahman M, Pizer ES, et al., Candidate serous cancer precursors in fallopian tube epithelium of BRCA1/2 mutation carriers. Mod Pathol 2009; 22: 1133-1138.
6. Lee Y, Miron A, Drapkin R, et al., A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol 2007; 211: 26-35. (Pubitemid 46092026)
7. Jarboe E, Folkins A, Drapkin R, et al., Tubal and ovarian pathways to pelvic epithelial cancer: a pathological perspective. Histopathology 2008; 53: 127-138. (Pubitemid 352032762)
8. Chen EY, Mehra K, Mehrad M, et al., Secretory cell outgrowth, PAX2 and serous carcinogenesis in the Fallopian tube. J Pathol 2010; 222: 110-116.
9. Norquist BM, Garcia RL, Allison KH, et al., The molecular pathogenesis of hereditary ovarian carcinoma: alterations in the tubal epithelium of women with BRCA1 and BRCA2 mutations. Cancer 2010; 116: 5261-5271.
10. Graham K, de las Morenas A, Tripathi A, et al., Gene expression in histologically normal epithelium from breast cancer patients and from cancer-free prophylactic mastectomy patients shares a similar profile. Br J Cancer 2010; 102: 1284-1293.
11. Bellacosa A, Godwin AK, Peri S, et al., Altered gene expression in morphologically normal epithelial cells from heterozygous carriers of BRCA1 or BRCA2 mutations. Cancer Prev Res (Philadelphia) 2010; 3: 48-61.
12. Tone AA, Begley H, Sharma M, et al., Gene Expression profiles of luteal phase Fallopian tube epithelium from BRCA mutation carriers resemble high-grade serous carcinoma. Clin Cancer Res 2008; 14: 4067-4078.
13. Gentleman RC, Carey VJ, Bates DM, et al., Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 2004; 5: R80.
14. Irizarry RA, Bolstad BM, Collin F, et al., Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res 2003; 31: e15.
15. Calza S, Raffelsberger W, Ploner A, et al., Filtering genes to improve sensitivity in oligonucleotide microarray data analysis. Nucleic Acids Res 2007; 35: e102.
16. Spandidos A, Wang X, Wang H, et al., PrimerBank: a resource of human and mouse PCR primer pairs for gene expression detection and quantification. Nucleic Acids Res 2010; 38: D792-799.
17. Wang X, Seed B., A PCR primer bank for quantitative gene expression analysis. Nucleic Acids Res 2003; 31: e154.
18. May T, Virtanen C, Sharma M, et al., Low malignant potential tumors with micropapillary features are molecularly similar to low-grade serous carcinoma of the ovary. Gynecol Oncol 2010; 117: 9-17.
19. Tone AA, Virtanen C, Shaw PA, et al., Decreased progesterone receptor isoform expression in luteal phase fallopian tube epithelium and high-grade serous carcinoma. Endocr Relat Cancer 2011; 18: 221-234.
20. Benjamini Y, Yekutieli D., The control of the false discovery rate in multiple testing under dependency. Ann Statist 2001; 29: 1165-1188. (Pubitemid 33575263)
21. Kindelberger DW, Lee Y, Miron A, et al., Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am J Surg Pathol 2007; 31: 161-169. (Pubitemid 46175016)
22. Vang R, Shih Ie M, Kurman RJ., Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Adv Anat Pathol 2009; 16: 267-282.
23. Carlson JW, Jarboe EA, Kindelberger D, et al., Serous tubal intraepithelial carcinoma: diagnostic reproducibility and its implications. Int J Gynecol Pathol 2010; 29: 310-314.
24. Sehdev AS, Kurman RJ, Kuhn E, et al., Serous tubal intraepithelial carcinoma upregulates markers associated with high-grade serous carcinomas including Rsf-1 (HBXAP), cyclin E and fatty acid synthase. Mod Pathol 2010; 23: 844-855.
25. Kurman RJ, Shih Ie M., The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol 2010; 34: 433-443.
26. Przybycin CG, Kurman RJ, Ronnett BM, et al., Are all pelvic (nonuterine) serous carcinomas of tubal origin ? Am J Surg Pathol 2010; 34: 1407-1416.
27. Zhang S, Royer R, Li S, et al., Frequencies of BRCA1 and BRCA2 mutations among 1342 unselected patients with invasive ovarian cancer. Gynecol Oncol 2011; (in press).
28. Snyder M, Huang XY, Zhang JJ., Identification of novel direct Stat3 target genes for control of growth and differentiation. J Biol Chem 2007; 283: 3791-3798.
29. Grivennikov S, Karin E, Terzic J, et al., IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 2009; 15: 103-113.
30. Duan Z., Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer. Clin Cancer Res 2006; 12: 5055-5063. (Pubitemid 44453331)
31. Yu H, Pardoll D, Jove R., STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 2009; 9: 798-809.
32. Sitko JC, Yeh B, Kim M, et al., SOCS3 regulates p21 expression and cell cycle arrest in response to DNA damage. Cell Signal 2008; 20: 2221-2230.
33. Chen EY, Tran A, Raho CJ, et al., Histological 'progression' from low (LSIL) to high (HSIL) squamous intraepithelial lesion is an uncommon event and an indication for quality assurance review. Mod Pathol 2010; 23: 1045-1051.
34. Chen M-P, Chung F-M, Chang D-M, et al., Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2006; 91: 295-299. (Pubitemid 43069152)
35. Zerbini LF., GADD45 Deregulation in cancer: frequently methylated tumor suppressors and potential therapeutic targets. Clin Cancer Res 2005; 11: 6409-6413. (Pubitemid 41338976)
36. Liu YW, Chen CC, Wang JM, et al., Role of transcriptional factors Sp1, c-Rel, and c-Jun in LPS-induced C/EBPδ gene expression of mouse macrophages. Cell Mol Life Sci 2007; 64: 3282-3294.
37. Litvak V, Ramsey SA, Rust AG, et al., Function of C/EBPδ in a regulatory circuit that discriminates between transient and persistent TLR4-induced signals. Nat Immunol 2009; 10: 437-443.
38. Pawar SA, Sarkar TR, Balamurugan K, et al., C/EBPδ targets cyclin D1 for proteasome-mediated degradation via induction of CDC27/APC3 expression. Proc Natl Acad Sci USA 2010; 107: 9210-9215.
39. Wang J, Sarkar TR, Zhou M, et al., CCAAT/enhancer binding protein-δ (C/EBPδ, CEBPD)-mediated nuclear import of FANCD2 by IPO4 augments cellular response to DNA damage. Proc Natl Acad Sci USA 2010; 107: 16131-16136.
40. Rakoff-Nahoum S., Why cancer and inflammation ? Yale J Biol Med 2006; 79: 123-130.
41. Landen CN, Jr. , Birrer MJ, Sood AK., Early events in the pathogenesis of epithelial ovarian cancer. J Clin Oncol 2008; 26: 995-1005. (Pubitemid 351398093)
42. Agarwal R, Kaye SB., Expression profiling and individualisation of treatment for ovarian cancer. Curr Opin Pharmacol 2006; 6: 345-349.
43. Crijns AP, Duiker EW, de Jong S, et al., Molecular prognostic markers in ovarian cancer: toward patient-tailored therapy. Int J Gynecol Cancer 2006; 16 (suppl 1): 152-165.
44. Crijns AP, Fehrmann RS, de Jong S, et al., Survival-related profile, pathways, and transcription factors in ovarian cancer. PLoS Med 2009; 6: e24.
45. Eisenhauer EA., New targets and non-cytotoxics in ovarian cancer. Ann Oncol 2006; 17 (suppl 10): x247-250. (Pubitemid 44542017)